BR112021022602A2 - Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton - Google Patents

Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton

Info

Publication number
BR112021022602A2
BR112021022602A2 BR112021022602A BR112021022602A BR112021022602A2 BR 112021022602 A2 BR112021022602 A2 BR 112021022602A2 BR 112021022602 A BR112021022602 A BR 112021022602A BR 112021022602 A BR112021022602 A BR 112021022602A BR 112021022602 A2 BR112021022602 A2 BR 112021022602A2
Authority
BR
Brazil
Prior art keywords
methods
chronic spontaneous
tyrosine kinase
kinase inhibitor
spontaneous urticaria
Prior art date
Application number
BR112021022602A
Other languages
English (en)
Portuguese (pt)
Inventor
Vitaliti Garami Alessandra
Andrijana Radivojevic
Arvind Kinhikar
Bruno Bieth
Bruno Cenni
Julian Storim
Maciej Cabanski
Martin Kaul
Souvik Bhattacharya
De Buck Stefan
Thomas Severin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112021022602A2 publication Critical patent/BR112021022602A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021022602A 2019-05-23 2020-05-20 Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton BR112021022602A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112021022602A2 true BR112021022602A2 (pt) 2022-01-04

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022602A BR112021022602A2 (pt) 2019-05-23 2020-05-20 Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton

Country Status (22)

Country Link
US (2) US12419889B2 (https=)
EP (2) EP4599894A3 (https=)
JP (2) JP7568651B2 (https=)
KR (1) KR20220012281A (https=)
CN (1) CN113795255A (https=)
AU (2) AU2020280272B2 (https=)
BR (1) BR112021022602A2 (https=)
CA (1) CA3138081A1 (https=)
CL (1) CL2021003032A1 (https=)
DK (1) DK3972604T3 (https=)
ES (1) ES3039974T3 (https=)
FI (1) FI3972604T3 (https=)
HR (1) HRP20251001T1 (https=)
IL (1) IL286983B2 (https=)
LT (1) LT3972604T (https=)
MX (2) MX2021013942A (https=)
PL (1) PL3972604T3 (https=)
PT (1) PT3972604T (https=)
RS (1) RS67141B1 (https=)
SI (1) SI3972604T1 (https=)
TW (2) TW202537625A (https=)
WO (1) WO2020234782A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705719C (en) 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije

Also Published As

Publication number Publication date
TWI868139B (zh) 2025-01-01
SI3972604T1 (sl) 2025-09-30
US20220184074A1 (en) 2022-06-16
RS67141B1 (sr) 2025-09-30
KR20220012281A (ko) 2022-02-03
MX2021013942A (es) 2022-01-04
EP3972604B1 (en) 2025-06-04
CN113795255A (zh) 2021-12-14
EP4599894A2 (en) 2025-08-13
PT3972604T (pt) 2025-08-26
TW202110450A (zh) 2021-03-16
AU2025252618A1 (en) 2025-11-06
AU2020280272A1 (en) 2021-11-18
EP3972604A1 (en) 2022-03-30
JP2024178168A (ja) 2024-12-24
AU2020280272B2 (en) 2025-07-24
EP4599894A3 (en) 2025-11-12
DK3972604T3 (da) 2025-09-15
CA3138081A1 (en) 2020-11-26
MX2024014626A (es) 2025-01-09
CL2021003032A1 (es) 2022-09-09
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
LT3972604T (lt) 2025-09-10
WO2020234782A1 (en) 2020-11-26
JP7568651B2 (ja) 2024-10-16
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
IL286983A (en) 2021-12-01
ES3039974T3 (en) 2025-10-28
FI3972604T3 (fi) 2025-09-01
PL3972604T3 (pl) 2025-09-22
US12419889B2 (en) 2025-09-23
US20250375446A1 (en) 2025-12-11
TW202537625A (zh) 2025-10-01

Similar Documents

Publication Publication Date Title
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BR112022025139A2 (pt) Inibidores de egfr alostéricos e métodos de uso dos mesmos
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112017019790A2 (pt) terapia combinada otimizada e uso da mesma para tratar câncer e doença autoimune
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201790122A1 (ru) Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112021024380A2 (pt) Formulações de liberação modificadas e usos das mesmas
PH12016502353A1 (en) Pharmaceutical composition
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
TW201613577A (en) Pharmaceutical combinations
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
BR112023025738A2 (pt) Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]